Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln

Pfizer's acquisition of exclusive rights to commercialize an obesity therapy in China for up to USD 495 million indicates a strategic expansion into a rapidly growing market.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

US President Trump's 10% global tariff rate takes effect

Hong Kong government strongly protests Panama's takeover of both Panama ports controlled by CK Hutchison (1 HK)

Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln

Standard Chartered (2888 HK) Q4 (USD) adj. pre-tax 1.24bln (exp. 1.38bln), oper. rev. 4.85bln (exp. 4.91bln), FY2025 profit attributable rose 25.6% Y/Y to 5.1bln, Co. announces additional USD 1.5bln share buyback

Japan's Finance Ministry is said to mull tweaking liquidity-enhancement auctions and reduce super-long supply further to steady yields

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal not only enhances Pfizer's product portfolio but could also signal increased competition in the obesity treatment sector, potentially impacting peer valuations and market dynamics in the broader pharmaceuticals space.

Related headlines

The whole workspace, free to try.

Try it free